Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407853 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29376536 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL119481 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL30055069 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL25358998 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398353 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398346 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31689003 | 0.93 | MDM2 (0.50) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29398655 | 0.92 | TLR2 (0.48) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL14417867 | 0.91 | CASP3 (0.46) | MDM4TP53TLR2CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667483-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024172166-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | ＪＣＲファーマ株式会社 | 2024-08-22 | — | — | WO | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-112188902-A | Modified self-immolative moieties for prodrugs and conjugates and methods of use and manufacture | 百时美施贵宝公司 | 2021-01-05 | — | — | CN | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-6040323-A | INHIBITING CELL PROLIFERATION OF HUMAN BREAST CANCER CELLS | UNIVERSITY OF PITTSBURGH (US) | 2000-03-21 | — | — | US | disclosed |
| EP-0959884-A4 | — | — | 1999-12-15 | — | — | EP | disclosed |
| EP-0959884-A1 | PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5925660-A | ENZYME INHIBITORS FOR PHOSPHATASE | UNIVERSITY OF PITTSBURGH (US) | 1999-07-20 | — | — | US | disclosed |
| US-5856506-A | (OXAZOLYLCARBONYLAMINO)ETHYLAMINO GLUTAMATE DERIVATIVES | UNIVERSITY OF PITTSBURGH (US) | 1999-01-05 | — | — | US | disclosed |
| WO-1998004257-A1 | PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5700821-A | INHIBIT CELL PROLIFERATION | UNIVERSITY OF PITTSBURGH (US) | 1997-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885TLR2 3821/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885TLR2 3821/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM4 1294/4885TP53 178/4885TLR2 4611/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885TLR2 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.